Literature DB >> 2732923

Advantages and limitations of current soft intraocular lenses.

A C Neumann1, B Cobb.   

Abstract

We report our clinical experience with six soft intraocular lenses: (1) STAAR silicone, (2) CooperVision/Schlegel silicone, (3) IOLAB silicone, (4) Allergan Medical Optics (AMO) silicone, (5) Fyodorov silicone, and (6) Alcon hydrogel (IOGEL). We found that these soft intraocular lenses have several common design problems. The single-size design of five of the six soft lenses can lead to a windshield-wiper decentration effect in lenses too small for larger eyes. We observed several instances in which the one-piece lenses became decentered, subluxed, and vaulted anteriorly against the iris or posteriorly away from the iris as postoperative capsulozonular changes occurred. We found that the insertion methods for these soft lenses need refining to reduce the risk of intraocular damage and wound stretching if the lenses are to be folded and inserted through a small 3.0 mm to 3.5 mm incision. The surface and physical characteristics of these lenses may also require further study. We observed folding grooves, sebacium deposits, and rust from the insertion instrument on some lenses inside the postoperative eye and pigment dispersion associated with hydrogel lenses. We conclude that small diameter polymethylmethacrylate implants are the best choice for small incision cataract surgery at this time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732923     DOI: 10.1016/s0886-3350(89)80082-3

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

1.  Clinical results with three different kinds of small optic PMMA-IOLs.

Authors:  M Amon; R Menapace; U Radax; P Papapanos
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

2.  A comparison of 141 polymacon (Iogel) and 140 poly(methyl methacrylate) intraocular lens implants.

Authors:  K J Lowe; D L Easty
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.